CD8A and neoplasm: Although PD-L1 and tumor mutation burden (TMB) can indicate the effect of immunotherapy to some extent (32), different types of immune cells in the tumor microenvironment, such as CD8+ T-cell infiltration, usually indicate that immunotherapy confers a good response and prognosis (33).